Rotenone was assessed in 2000 because of its MPTP-like inhibition of mitochondrial complex I [14]. However, since its introduction, rotenone has been under serious debate [26]. Like MPTP, rotenone readily crosses the BBB, where it causes oxidative stress and accumulates inside the mitochondria dopaminergic neurons. However, the resulting reduction in ATP is not a cause of cell death. Rather, a large amount of ROS accounts for the damage in the SN region [27]. One important benefit of the rotenone model is that some investigators have reported the accumulation of